2021 KUMC Virtual Multidisciplinary Oncology Review


 

KUMC Updated Data on mCRPC: Cabazitaxel vs. Abiraterone/Enzalutamide, Lu-177 vs. Cabazitaxel, Olaparib vs. Enzalutamide/Abiraterone, Rucaparib for BRCA Alterations

27 views
May 17, 2021
Comments 0
Login to view comments. Click here to Login